Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

diabetic cancer patients

  • You have access
    Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
    CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA
    Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire